1. OP0179 Brafv600e promotes myeloid skewing in multisystemic langerhans cell histiocytosis humanized mouse model. (15th June 2017) Authors: Biavasco, R; Norelli, M; Camisa, B; Cesana, D; Gallina, P; Gentner, B; Ponzoni, M; Dagna, L; Bondanza, A; Montini, E Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 126 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OS05.6.A Modification of the tumor microenvironment in patients with glioblastoma using autologous, genetically modified, hematopoietic stem cell-based therapy: the TEM-GBM STUDY (NCT03866109). (5th September 2022) Authors: Finocchiaro, G; Eoli, M; Gentner, B; Bruzzone, M; Di Meco, F; Mortini, P; Olivi, A; Naldini, L; Russo, C; Ciceri, F Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P05.02 A phase I/IIa dose escalation study evaluating the safety and efficacy of autologous CD34+ enriched hematopoietic progenitor cells genetically modified for human interferon-α2 in patients with GBM and an unmethylated MGMT promoter (TEM-GBM-001). (6th September 2019) Authors: Gentner, B; Ciceri, F; DiMeco, F; Legnani, F; Eoli, M; Pollo, B; Farina, F; Mazzoleni, S; Russo, C; Naldini, L; Finocchiaro, G Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 3 Page Start: iii34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗